| Literature DB >> 35005650 |
Etienne Lavallée1,2, Zach Dovey1, Prachee Pathak1, Linda Dey3,4, Lotta Renström Koskela3,4, Arad Hosseini3, Nikhil Waingankar1, Reza Mehrazin1, John Sfakianos1, Abolfazl Hosseini3,4, Peter Wiklund1,3,4.
Abstract
BACKGROUND: For females undergoing cystectomy and urinary diversion, decreases in sexual and urinary functions can have a significant impact on quality of life. Pelvic organ-preserving (POP) radical cystectomy (RC) has been proposed as an approach to improve postoperative functional outcomes.Entities:
Keywords: Bladder cancer; Cystectomy; Female cystectomy; Neobladder; Sexual function; Urinary diversion; Urinary function
Year: 2021 PMID: 35005650 PMCID: PMC8718832 DOI: 10.1016/j.euros.2021.11.010
Source DB: PubMed Journal: Eur Urol Open Sci ISSN: 2666-1683
Fig. 1Pelvic organ–preserving robot-assisted radical cystectomy. (A) Incision of the peritoneum at the junction between the bladder and the vagina. (B) Dissection of the plane between the bladder and the vagina. (C) Transection of the left bladder pedicle with preservation of the lateral aspect of the vagina. (D) Transection of the proximal urethra.
Fig. 2Orthotopic neobladder reconstruction. (A) Posterior aspect of the urethroileal anastomosis. (B) Isolation of a segment of ileum extending 40 cm proximal and 10 cm distal to the urethroileal anastomosis. Preserved round ligaments can be seen extending outwards bilaterally. (C) Wallace ureteroileal anastomosis at the proximal end of the neobladder chimney. (D) Leak test performed on the completed neobladder.
Patient characteristics
| Parameter | Result | |
|---|---|---|
| Median age at surgery, yr (range) | 54 (34–79) | 23 |
| Median body mass index, kg/m2 (range) | 23.6 (18.2–33.1) | |
| Smoking status, | 23 | |
| Never smoked | 4 (17) | |
| Former smoker | 7 (30) | |
| Current smoker | 12 (52) | |
| American Society of Anesthesiologists score, | 23 | |
| 1 | 5 (22) | |
| 2 | 13 (57) | |
| 3 | 5 (22) | |
| Prior bacillus Calmette-Guérin therapy, | 7 (30) | 23 |
| Clinical stage, | 23 | |
| Tis/Ta/T1 | 10 (43) | |
| T2 | 13 (57) | |
| T3 | 0 | |
| T4 | 0 | |
| Neoadjuvant chemotherapy, | 13 (57) | 23 |
| pT stage, | 23 | |
| T0 | 11 (48) | |
| Tis/Ta/T1 | 2 (9) | |
| T2 | 7 (30) | |
| T3 | 3 (13) | |
| T4 | 0 | |
| pN stage, | 22 | |
| pN0 | 19 (86) | |
| pN1 | 3 (14) | |
| Positive margin, | 1 (4) | 23 |
| Median operating time, min (range) | 300 (250–390) | 21 |
| Median blood loss, ml (range) | 100 (10–600) | 23 |
| Urinary diversion, | 23 | |
| Ileal conduit | 3 (13) | |
| Neobladder | 20 (87) | |
| Median hospital stay, d (range) | 6 (3–16) | 23 |
| Surgical complications, | 23 | |
| Grade 2 | 8 (35) | |
| Grade 3–5 | 0 (0) | |
| Median follow-up, mo (range) | 20 (7–151) | 23 |
| Disease recurrence, | 4 (17) | 23 |
| Median time to disease recurrence, mo (range) | 13 (11–28) | 4 |
| Disease-specific mortality, | 2 (9) | 23 |
One patient had a positive left ureteral margin.
Two patients died of recurrent bladder cancer, one at 20 mo and one at 36 mo after surgery.
Fig. 3Frequency of sexual activity (penetration or self-stimulation) reported following surgery.
Urinary function following surgery for the 20 patients with neobladder reconstruction
| Parameter | Patients, |
|---|---|
| Pad use per day | |
| 0–1 pads | 14 (70) |
| 2–4 pads | 4 (20) |
| ≥5 pads | 2 (10) |
| Nighttime continence | |
| Yes | 16 (80) |
| No | 4 (20) |
| Need for clean intermittent catheterization | |
| Yes | 10 (50) |
| No | 10 (50) |
Nighttime continence was defined as ≤1 protection pads per night.